Does Orforglipron Treat Sleep Apnea?

Does orforglipron treat sleep apnea? No — per its FDA-approved label on DailyMed, Foundayo (orforglipron) is approved only for chronic weight management, and obstructive sleep apnea is not a listed indication. That’s a meaningful distinction, because a different GLP-1-class medication, tirzepatide (Zepbound), does carry an FDA-approved sleep apnea indication — and the two get confused often enough that it’s worth spelling out clearly.

What orforglipron is actually approved for

Orforglipron (brand name Foundayo, Eli Lilly) is a once-daily oral GLP-1 receptor agonist. Per its FDA-approved label on DailyMed, it’s indicated for chronic weight management in adults with obesity, or who are overweight with at least one weight-related condition, used alongside diet and physical activity. The label does not include an obstructive sleep apnea (OSA) indication. If you’re researching orforglipron because of a sleep apnea diagnosis specifically, it’s worth knowing upfront that this isn’t what the drug was studied or approved for.

The medication that actually has a sleep apnea indication

Tirzepatide — sold under the brand names Mounjaro (type 2 diabetes) and Zepbound (weight management and obstructive sleep apnea) — is a dual GIP/GLP-1 receptor agonist, not a single-receptor drug like orforglipron. Per MedlinePlus’s tirzepatide drug information, tirzepatide is used to treat obstructive sleep apnea in adults with obesity, in addition to its weight-management and diabetes uses. That indication came from a dedicated clinical trial program studying tirzepatide specifically in OSA patients — a different approval pathway than orforglipron went through.

This is the core distinction to keep straight: orforglipron and tirzepatide are both incretin-based medications used for weight management, but only tirzepatide has cleared the bar for an FDA-approved sleep apnea claim. For a broader look at how the two drugs differ mechanistically, see Orforglipron vs Tirzepatide.

Side-by-side: approved indications

	Orforglipron (Foundayo)	Tirzepatide — Zepbound	Semaglutide — Wegovy/Ozempic
Receptor mechanism	GLP-1 (single receptor)	GIP/GLP-1 (dual receptor)	GLP-1 (single receptor)
Chronic weight management	Approved	Approved	Approved (Wegovy)
Type 2 diabetes	Not approved	Approved (as Mounjaro)	Approved (as Ozempic)
Obstructive sleep apnea	Not approved	Approved (Zepbound)	Not approved

Sources: FOUNDAYO FDA label (DailyMed) and the MedlinePlus tirzepatide and semaglutide-injection pages, linked below.

Why weight-loss drugs and sleep apnea come up together at all

Obstructive sleep apnea happens when tissue around the airway relaxes and narrows or blocks airflow during sleep, and excess weight around the neck and airway is one of the best-established risk factors for it. That’s the biological reason weight-management medications, as a category, get discussed in the same breath as OSA treatment — significant weight loss is a recognized way to reduce OSA severity for many people, independent of which drug produced the weight loss.

That general connection is different from a drug having an FDA-approved OSA indication, though. Tirzepatide earned that specific claim through its own trial program. Orforglipron’s approval is for weight management, and any effect on OSA symptoms it might have would be a secondary consequence of weight loss — not something evaluated or claimed on its label. If sleep apnea is a primary concern driving your medication choice, that’s an important difference to raise directly with your prescriber, and Who Should Take Orforglipron covers the broader picture of who the drug is — and isn’t — approved for.

What this means if you have both obesity and sleep apnea

If you’re managing both conditions, a few things are worth keeping separate in your head:

• Orforglipron losing you weight doesn’t automatically mean your OSA is being “treated.” Weight loss can improve OSA severity for many people, but it isn’t guaranteed to resolve it, and there’s no orforglipron-specific data claiming it does.
• Don’t adjust CPAP therapy on your own based on weight loss. Whether your CPAP settings should change — or whether you might eventually need less or no CPAP support — is a decision for your sleep physician, typically confirmed with a follow-up sleep study rather than assumed from the scale.
• If sleep apnea is your primary reason for wanting a GLP-1-class medication, ask your doctor about the on-label option. Zepbound (tirzepatide) is the one with an FDA-approved OSA indication; that’s a relevant fact to bring into that specific conversation, even though only your prescriber can weigh it against your full history.

For general background on how oral GLP-1 medications compare to injectable ones beyond this specific question, see GLP-1 Pill vs Injection: What’s Actually Different.

Questions worth bringing to your prescriber

Since orforglipron’s label doesn’t address sleep apnea directly, the more useful conversation happens with your care team rather than a search result. A few things worth asking:

• Has my OSA severity been formally assessed? A sleep study (polysomnography or a home sleep apnea test) is what actually establishes a baseline and tracks change — not how you feel or how much weight you’ve lost.
• If I’m prioritizing sleep apnea specifically, is an on-label option like Zepbound worth discussing? Your prescriber can weigh that against your diabetes status, other health conditions, and insurance coverage, since tirzepatide’s approved uses differ by brand (Mounjaro for diabetes, Zepbound for weight management and OSA).
• If I stay on orforglipron, how will we know if my OSA is improving? That’s a question for your sleep physician, typically answered with a follow-up study rather than assumed from weight-loss progress alone.

None of these are questions this article can answer for you — they depend on your diagnosis, your current treatment, and your overall health picture, which only your care team has full visibility into.

Bottom line

Orforglipron (Foundayo) is not FDA-approved to treat obstructive sleep apnea — its approved use is chronic weight management. Tirzepatide (Zepbound) is the medication in this drug category with an actual FDA-approved OSA indication, earned through its own clinical trial program. Weight loss from any cause, including orforglipron, may help OSA severity for some people, but that’s a general mechanism, not a claim on orforglipron’s label. If sleep apnea is part of your health picture, bring it up directly with your prescriber and your sleep physician — they can look at the full picture, including whether an on-label option makes more sense for your situation. For more on what orforglipron is approved and used for, see Orforglipron Weight Loss: What to Expect.